December 2008 Volume 26 Number 12, pp 1313 - 1388
Visit Nature Biotechnology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=56&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access to Nature Biotechnology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=28&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=40&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Bioentrepreneur: an online resource for budding business in the life sciences.
http://links.ealert.nature.com/ctt?kn=6&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
The Master in Biotechnology Management at IE Business School offers the ideal combination of business knowledge
and specialized industry know-how needed to meet the challenges of today's biotech industry. Our online methodology mirrors reality: cross-cultural teams work on global projects regardless of their geographic location.
Build your career without breaking away from it.
http://links.ealert.nature.com/ctt?kn=27&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
BIOPARTNERING
Visit our Biopartnering site to view Company Profiles and Partnership Opportunities:
=====================================================================
=========================== ADVERTISEMENT ===========================
SciBX
Now available online! Visit www.scibx.com for free access to the full contents of SciBX this month.
SciBX: Science-Business eXchange - new from the makers of Nature and BioCentury
=====================================================================
----------------------
EDITORIAL
----------------------
Yes we can as well p1313
If biotech is to remain a wellspring of innovation, industry and academia need to do more to cultivate the next generation of entrepreneurial minds.
doi:10.1038/nbt1208-1313
http://links.ealert.nature.com/ctt?kn=90&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
----------------------
NEWS
----------------------
FDA launches priority vouchers for neglected-disease drugs pp1315 - 1316
Emily Waltz
doi:10.1038/nbt1208-1315
http://links.ealert.nature.com/ctt?kn=37&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Ustekinumab poised to enter the psoriasis market pp1317 - 1318
Charlie Schmidt
doi:10.1038/nbt1208-1317a
http://links.ealert.nature.com/ctt?kn=66&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
German BioPharma awards p1317
Susan Aldridge
doi:10.1038/nbt1208-1317b
http://links.ealert.nature.com/ctt?kn=44&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Europe lags, US leads 2nd-generation biofuels pp1319 - 1321
Cormac Sheridan
doi:10.1038/nbt1208-1319
http://links.ealert.nature.com/ctt?kn=54&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Oslo's cancer leap p1320
Hayley Birch
doi:10.1038/nbt1208-1320a
http://links.ealert.nature.com/ctt?kn=17&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Cell/gene potency guides p1320
Asher Mullard
doi:10.1038/nbt1208-1320b
http://links.ealert.nature.com/ctt?kn=20&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
California bill abets biotech p1322
Brady Huggett
doi:10.1038/nbt1208-1322a
http://links.ealert.nature.com/ctt?kn=25&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Biomarkers' double edge p1322
Jeffrey L Fox
doi:10.1038/nbt1208-1322b
http://links.ealert.nature.com/ctt?kn=110&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Shire dumps Dynepo pp1322 - 1323
Mark Ratner
doi:10.1038/nbt1208-1322c
http://links.ealert.nature.com/ctt?kn=87&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Country-of-origin labels p1323
Susan Kim
doi:10.1038/nbt1208-1323a
http://links.ealert.nature.com/ctt?kn=50&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Giants wrestle over ImClone p1323
George S Mack
doi:10.1038/nbt1208-1323b
http://links.ealert.nature.com/ctt?kn=109&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
PROFILE
Alan Alda p1325
Alan Alda is not only a beloved actor, producer, writer and activist, but also a skilled science communicator. Those aiming to talk effectively to the public about biotech research would do well to follow his lead.
George S Mack
doi:10.1038/nbt1208-1325
http://links.ealert.nature.com/ctt?kn=62&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
DATA PAGE
Biotech patents - business as usual? p1326
Stacy Lawrence
doi:10.1038/nbt1208-1326
http://links.ealert.nature.com/ctt?kn=121&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
NEWS FEATURE
Hypertension's shot in the arm pp1327 - 1329
Two small companies developing therapeutic vaccines against hypertension are blazing a trail for immune treatments that address diseases of lifestyle with massive markets. But doubts linger over the safety of eliciting an immune response to normal body constituents. Jill U. Adams investigates.
Jill U. Adams
doi:10.1038/nbt1208-1327
http://links.ealert.nature.com/ctt?kn=22&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
----------------------
BIOENTREPRENEUR
----------------------
BUILDING A BUSINESS
Moving on pp1331 - 1333
As a company grows, the founding scientist sometimes discovers (and investors often hint) that it's time to leave the CEO spot and hand it to someone with more business experience. To ease the possible shock of the process, consider this transition from day one.
Jennie Mather
doi:10.1038/bioe.2008.10
http://links.ealert.nature.com/ctt?kn=122&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
----------------------
OPINION AND COMMENT
----------------------
CORRESPONDENCE
Protest and 'democracy' p1335
Jan Laufer
doi:10.1038/nbt1208-1335a
http://links.ealert.nature.com/ctt?kn=61&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Reply to Protest and 'democracy' p1335
doi:10.1038/nbt1208-1335b
http://links.ealert.nature.com/ctt?kn=38&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Foot and Mouth's Achilles' heel? pp1335 - 1336
John F Atkins and Martin D Ryan
doi:10.1038/nbt1208-1335c
http://links.ealert.nature.com/ctt?kn=76&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Automated de novo protein sequencing of monoclonal antibodies pp1336 - 1338
Nuno Bandeira et al.
doi:10.1038/nbt1208-1336
http://links.ealert.nature.com/ctt?kn=60&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
PhosphoPep - a database of protein phosphorylation sites in model organisms pp1339 - 1340
Bernd Bodenmiller et al.
doi:10.1038/nbt1208-1339
http://links.ealert.nature.com/ctt?kn=24&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
----------------------
FEATURES
----------------------
PATENTS
Antibody patenting without antibodies: a global trend pp1341 - 1343
Granting human gene patents that include broad antibody claims without any experimental antibody production makes the gene patent issue more complex.
Kazunori Hashimoto and Tomomi Aida
doi:10.1038/nbt1208-1341
http://links.ealert.nature.com/ctt?kn=32&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Recent patent applications in protein purification p1344
doi:10.1038/nbt1208-1344
http://links.ealert.nature.com/ctt?kn=49&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Microfluidics closes in on point-of-care assays pp1345 - 1346
An integrated microfluidic device enables rapid detection of protein biomarkers in patient samples.
Peter K Sorger
doi:10.1038/nbt1208-1345
http://links.ealert.nature.com/ctt?kn=35&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
MicroRNAs fine-tune oncolytic viruses pp1346 - 1348
Targeting by tissue-specific microRNAs enhances the efficacy and safety of tumor-killing viruses.
John C Bell and David Kirn
doi:10.1038/nbt1208-1346
http://links.ealert.nature.com/ctt?kn=57&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Cancer and complement pp1348 - 1349
A component of the complement system promotes tumor growth by activating myeloid-derived suppressor cells.
Suzanne Ostrand-Rosenberg
doi:10.1038/nbt1208-1348
http://links.ealert.nature.com/ctt?kn=80&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Research Highlights p1350
doi:10.1038/nbt1208-1350
http://links.ealert.nature.com/ctt?kn=108&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
----------------------
RESEARCH
----------------------
ANALYSIS
Design and analysis of ChIP-seq experiments for DNA-binding proteins pp1351 - 1359
Peter V Kharchenko, Michael Y Tolstorukov and Peter J Park
doi:10.1038/nbt.1508
Abstract: http://links.ealert.nature.com/ctt?kn=113&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=63&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
BRIEF COMMUNICATIONS
Recurrent chromosomal abnormalities in human embryonic stem cells pp1361 - 1363
During long-term culture, human embryonic stem (hES) cells may acquire chromosomal abnormalities that compromise their potential clinical utility. A study of 17 hES cell lines reveals various genomic changes, including trisomies and monosomies, an amplification at 20q11.21 and a derivative chromosome 18.
Claudia Spits et al.
doi:10.1038/nbt.1510
Abstract: http://links.ealert.nature.com/ctt?kn=119&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=5&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Human embryonic stem cells reveal recurrent genomic instability at 20q11.21 pp1364 - 1366
During long-term culture, human embryonic stem (hES) cells may acquire chromosomal abnormalities that compromise their potential clinical utility. Lefort et al. show that an amplification at 20q11.21 arose at relatively late passage number in three of five hES cell lines.
Nathalie Lefort et al.
doi:10.1038/nbt.1509
Abstract: http://links.ealert.nature.com/ctt?kn=29&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=111&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
ARTICLE
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification pp1367 - 1372
Cox and Mann describe MaxQuant, a suite of algorithms for the analysis of high-resolution mass spectrometry data. The approach achieves substantial improvements in the accuracy of mass measurements and the peptide identification rate.
Jurgen Cox and Matthias Mann
doi:10.1038/nbt.1511
Abstract: http://links.ealert.nature.com/ctt?kn=112&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=34&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
LETTERS
Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood pp1373 - 1378
Fan et al. describe a microfluidic chip for multiplexed analysis of proteins in a finger prick of blood. The chip separates plasma from diluted whole blood and quantifies panels of serum proteins in about 10 minutes, minimizing protein degradation.
Rong Fan et al.
doi:10.1038/nbt.1507
Abstract: http://links.ealert.nature.com/ctt?kn=86&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=39&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Asymmetric RNA duplexes mediate RNA interference in mammalian cells pp1379 - 1382
Gene silencing by siRNA generally relies on short RNA duplexes containing two strands of the same length. Sun et al. show that an asymmetric duplex with a shortened passenger strand silences its target gene effectively while reducing off-target effects mediated by this strand.
Xiangao Sun, Harry A Rogoff and Chiang J Li
doi:10.1038/nbt.1512
Abstract: http://links.ealert.nature.com/ctt?kn=128&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=123&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
----------------------
ERRATA
----------------------
Erratum: Where to float? p1383
Nuala Moran
doi:10.1038/nbt1208-1383a
http://links.ealert.nature.com/ctt?kn=2&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Erratum: Reply to Field-evolved resistance to Bt toxins p1383
Bruce E Tabashnik, Aaron J Gassman, David W Crowder and Yves Carriere
doi:10.1038/nbt1208-1383b
http://links.ealert.nature.com/ctt?kn=8&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
Erratum: Actemra poised to launch IL-6 inhibitors p1383
Lisa Melton and Amy Coombs
doi:10.1038/nbt1208-1383c
http://links.ealert.nature.com/ctt?kn=11&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
----------------------
NATUREJOBS
----------------------
CAREERS AND RECRUITMENT
Development translates discoveries into products pp1385 - 1386
Product development teams take research discoveries to the next level.
Mark Johnson
doi:10.1038/nbt1208-1385
http://links.ealert.nature.com/ctt?kn=73&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
PEOPLE
People p1388
doi:10.1038/nbt1208-1388
http://links.ealert.nature.com/ctt?kn=21&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
The Miami 2009 Winter Symposium
Interpreting the Human Genome
January 24-28, 2009
Deauville Beach Resort - Miami Beach, FL, USA
This meeting will showcase these advances in our understanding of human genome regulation and variability as well as the potential of new technologies to drive the advancement of knowledge.
For more information and to register visit:
http://links.ealert.nature.com/ctt?kn=104&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
anatureconference
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to
receive it. You can change or discontinue your e-mail alerts at any time,
by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=18&m=30643828&r=MTM4MDA0OTcyOQS2&b=2&j=NDM3NjUzMDMS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2008 Nature Publishing Group
=====================================================================
